EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have ...

combining an EGFR-binding domain at one end with one targeting mesenchymal epithelial transition (MET) factor, which is a common resistance mechanism that can reduce the activity of EGFR drugs.

Radiosensitization by EGFR inhibitors might be mediated by effects on cell proliferation, survival, angiogenesis, and DNA repair. Improved understanding of the mechanisms of radiosensitization ...

Mechanisms of resistance to third-generation EGFR TKIs like osimertinib are very heterogeneic, explained Vamsidhar Velcheti, MD, of NYU Langone's Perlmutter Cancer Center in New York City.

Caption Scientists from Hiroshima University and University of California, San Diego have discovered the mechanism by which EGFR activates YAP/TAZ. Their results suggest that the combination of ...